These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29623548)

  • 21. [The harmfulness of drugs and slimming substances--a toxicologist's point of view].
    Kujawa A; Szponar J; Szponar E; Zapalska-Pozarowska K; Kostek H
    Przegl Lek; 2012; 69(8):548-51. PubMed ID: 23243925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-obesity drug development.
    Bays H; Dujovne C
    Expert Opin Investig Drugs; 2002 Sep; 11(9):1189-204. PubMed ID: 12225242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiobesity effects of green tea catechins: a mechanistic review.
    Rains TM; Agarwal S; Maki KC
    J Nutr Biochem; 2011 Jan; 22(1):1-7. PubMed ID: 21115335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medicinal strategies in the treatment of obesity.
    Bray GA; Tartaglia LA
    Nature; 2000 Apr; 404(6778):672-7. PubMed ID: 10766254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Past, present and future of obesity pharmacotherapy].
    Fábryová L
    Vnitr Lek; 2010 Oct; 56(10):1058-64. PubMed ID: 21105452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug strategies for the treatment of obesity.
    Alemany M; Remesar X; Fernández-López JA
    IDrugs; 2003 Jun; 6(6):566-72. PubMed ID: 12811679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brown adipose tissue: a potential target in the fight against obesity and the metabolic syndrome.
    Poekes L; Lanthier N; Leclercq IA
    Clin Sci (Lond); 2015 Dec; 129(11):933-49. PubMed ID: 26359253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Targets for Drug Treatment of Obesity.
    Valsamakis G; Konstantakou P; Mastorakos G
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():585-605. PubMed ID: 28061687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obesity pharmacotherapy: what is next?
    Colon-Gonzalez F; Kim GW; Lin JE; Valentino MA; Waldman SA
    Mol Aspects Med; 2013 Feb; 34(1):71-83. PubMed ID: 23103610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current pharmacotherapy for obesity.
    Srivastava G; Apovian CM
    Nat Rev Endocrinol; 2018 Jan; 14(1):12-24. PubMed ID: 29027993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New molecular targets in the pathophysiology of obesity and available treatment options under investigation.
    Valsamakis G; Lois K; Kumar S; Mastorakos G
    Clin Obes; 2014 Aug; 4(4):209-19. PubMed ID: 25826792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obesity-An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances.
    Gjermeni E; Kirstein AS; Kolbig F; Kirchhof M; Bundalian L; Katzmann JL; Laufs U; Blüher M; Garten A; Le Duc D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting energy expenditure in muscle as a means of combating obesity.
    Clarke IJ; Henry BA
    Clin Exp Pharmacol Physiol; 2010 Jan; 37(1):121-4. PubMed ID: 19650796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical management of obesity.
    Giri M
    Acta Clin Belg; 2006; 61(5):286-94. PubMed ID: 17240746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice.
    Fukuda-Tsuru S; Kakimoto T; Utsumi H; Kiuchi S; Ishii S
    Eur J Pharmacol; 2014 Jan; 723():207-15. PubMed ID: 24309217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging aspects of pharmacotherapy for obesity and metabolic syndrome.
    Nisoli E; Carruba MO
    Pharmacol Res; 2004 Nov; 50(5):453-69. PubMed ID: 15458765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S134-41. PubMed ID: 26654857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanotechnology-Mediated Drug Delivery for the Treatment of Obesity and Its Related Comorbidities.
    Tsou YH; Wang B; Ho W; Hu B; Tang P; Sweet S; Zhang XQ; Xu X
    Adv Healthc Mater; 2019 Jun; 8(12):e1801184. PubMed ID: 30938934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An update in the management of obesity: the weight of CNS targets.
    Bariohay B; Roux JA; Bonnet MS; Dallaporta M; Troadec JD
    Recent Pat CNS Drug Discov; 2011 Sep; 6(3):164-80. PubMed ID: 21834783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obesity medications: what does the future look like?
    Butsch WS
    Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):360-6. PubMed ID: 26313898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.